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Weight loss at altitude might result
from an evolutionary adaptation
Andrew J. Murray1)* and Hugh E. Montgomery2)At extreme altitude (>5,000 — 5,500m), sustained hypoxia threatens human
function and survival, and is associated with marked involuntary weight loss
(cachexia). This seems to be a coordinated response: appetite and protein
synthesis are suppressed, and muscle catabolism promoted. We hypothesise
that, rather than simply being pathophysiological dysregulation, this cachexia is
protective. Ketone bodies, synthesised during relative starvation, protect tissues
such as the brain from reduced oxygen availability by mechanisms including
the reduced generation of reactive oxygen species, improved mitochondrial
efficiency and activation of the ATP-sensitive potassium (KATP) channel. Amino
acids released from skeletal muscle also protect cells from hypoxia, and may
interact synergistically with ketones to offer added protection. We thus propose
that weight loss in hypoxia is an adaptive response: the amino acids and ketone
bodies made available act not only as metabolic substrates, but as metabolic
modulators, protecting cells from the hypoxic challenge.amino acids; catabolism; hypoxia; keKeywords:tones; metabolism; muscleIntroduction
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under the terms of the Crea
oduction in any medium, proavailability of high altitude (hypobaric
hypoxia) relies not just on mechanisms
to sustain oxygen delivery to the
tissues [1], but on alterations to oxygenAbbreviations:
AcAc, acetoacetate; AMPK, AMP-activated pro-
tein kinase;AMS, acutemountain sickness;ARNT,
aryl hydrocarbon receptor nuclear translocator;
CCK, cholecystokinin; COPD, chronic obstructive
pulmonary disease; HIF, hypoxia-inducible factor;
ICU, intensive care unit; KATP channel, ATP-
sensitive potassium channel; mTOR, mammalian
target-of-rapamycin; mTORC1, mTOR complex I;
b-OHB, b-hydroxybutyrate; PPARa, peroxisome
proliferator-activated receptor a; ROS, reactive
oxygen species; RQ, respiratory quotient; SUR,
sulfonylurea receptor; UCP, uncoupling protein.
ioessays published by WILEY Periodicals, Inc. Th
tive Commons Attribution License, which permits
vided the original work is properly cited.use [2, 3]. Both mechanisms are regu-
lated, at least in part, by the hypoxia
inducible factor (HIF) family of tran-
scription factors, which drive the
expression of (thus) ‘hypoxia-sensitive’
genes [4].Weight loss at altitude results
partly from decreased energy
intake
Hypoxia (whether normobaric or hypo-
baric) is associated with significant
involuntary fat and muscle loss [5, 6]
to which a variety of factors, including
exertional metabolic demands and
elevated basal metabolic rate, may
contribute [7–9]. However, whilst alti-
tude exposure increases perceived
exercise intensity, actual energy ex-
penditure is much lower, with oxygen
consumption rates falling as altitude
increases [10]. Meanwhile, malabsorp-
tion of nutrients and a reduction in
appetite – perhaps partly mediated
through increased circulating levels of
the satiety hormones cholecystokinin
(CCK) [11] and leptin [12] – reduce
energy intake by as much as half
[5, 13]. Decreased energy intake thus
appears to be the dominant cause
of weight loss at altitude (albeit
that overall energy expenditure
might rise as total exertional load
increases), particularly since any in-
crease in activity does not seem to
elicit a corresponding increase in
energy intake [10] and since diet-
induced thermogenesis also falls along
with intake [9].www.bioessays-journal.com 721is is an
use,
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muscle mass is greater than fat
loss
At higher altitudes (above 5,000–
5,500m), loss of muscle mass accounts
for a greater proportion (66–73%) of
overall weight loss than does fat loss [5,
6], perhaps as a result of additional,
evolutionarily ubiquitous, direct effects of
hypoxia on protein synthesis [14]. These
effects are mediated through inhibition of
gene transcription and translation [15]
and by induction of the metabolic sensor,
AMP kinase (AMPK), which inhibits
protein synthesis via the target-of-rapa-
mycin kinase (mTOR) pathway whilst
promoting muscle catabolism [16].Krebs
Cycle
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Figure 1. Pathways of amino acid breakdown. A: Some amino acids (e.g. glutamic acid/
glutamate) can undergo direct deamination to their corresponding keto-acids (e.g. a-
ketoglutaric acid/a-ketoglutarate). B: Most amino acids undergo initial transamination, with
the amino group transferred to a-ketoglutarate, to yield a ketoacid and glutamate, which can
then undergo direct deamination as above. C: The ketoacids resulting from the above
reactions are converted to a small number of metabolites that fuel the Krebs cycle. As such,
some amino acids are glucogenic (pink boxes), yielding glucose, whilst others are ketogenic
(green boxes) and yield acetoacetyl-CoA, and thus, ketone bodies. Note that some amino
acids can be either glucogenic or ketogenic. Ala, alanine; Arg – arginine; Asn, asparagine;
Asp, aspartate; Cys, cysteine; Gly, glycine; Gln, glutamine; His, histidine; Ile, isoleucine; Leu,
leucine; Lys, lysine; Met, methionine; Phe, phenylalanine; Pro, proline; Ser, serine; Thr,
threonine; Trp, tryptophan; Tyr, tyrosine; Val, valine.The consequences of
inadequate food intake and of
muscle breakdown
With inadequate food intake, lipolysis of
triacylglycerol stores releases sufficient
fatty acids that the quantities of acetyl-
CoA so generated can overwhelm the
Krebs cycle. In this instance, acetyl-CoA
is diverted towards hepatic ketone bio-
synthesis, yielding acetoacetate (AcAc)
and b-hydroxybutyrate (b-OHB). In the
mitochondria of distant tissues, such as
brain and heart, the ketone bodies are
reconverted to acetyl-CoA for entry into
the Krebs cycle.
Meanwhile, protein breakdown
releases amino acids. Some amino acids
can undergo direct oxidative deamina-
tion to their corresponding ketoacids in
the liver (e.g. glutamate is converted to
a-ketoglutarate by glutamate dehydro-
genase, whilst glycine is converted to
glyoxylate by glycine oxidase), yielding
reduced NAD (NADH) and a free ammo-
nium ion (Fig. 1A), which is converted to
urea and excreted. Most amino acids,
however, are initially transaminated
rather than deaminated, the amino
group being transferred to a-ketogluta-
rate to yield a ketoacid and glutamate,
which can itself then undergo direct
deamination (Fig. 1B). The resulting
ketoacids – essentially the carbon skel-
etons of the deaminated amino acids –
enter pathways that converge on just a
handful of molecules that between them
fuel the Krebs cycle (Fig. 1C). Alanine,
serine, cysteine, tryptophan and gly-
cine, for instance, can yield pyruvate;722glutamine, proline, arginine and histi-
dine are converted to glutamate and
thence to a-ketoglutarate; whilst succi-
nyl-CoA, fumarate and oxaloacetate can
arise from other amino acids. Amino
acids that are degraded to these Krebs
cycle intermediates are termed gluco-
genic amino acids. Meanwhile, the so-
called ketogenic amino acids are con-
verted to acetoacetyl-CoA or acetyl-CoA,
and can give rise to ketone bodies.
Whilst only leucine and lysine, of the 20
canonical amino acids, are solely keto-
genic, isoleucine, phenylalanine, tryp-
tophan and tyrosine are both ketogenic
and glucogenic. Thus, protein catabo-
lism frommuscle breakdown can further
drive hepatic ketone biosynthesis.Bioessays 36: 721–729, 2014 The Authors. BioHypothesis
We propose that the catabolic response
to altitude (comprising both lipolytic
andmyolytic components) is orchestrat-
ed, and that it is both metabolically
advantageous and protective under
hypoxic conditions.Advantages of the
catabolic state
Improvements in oxygen
supply/demand matching
So what might be the advantages of
such a hypoxia-induced cachectic state?essays published by WILEY Periodicals, Inc.
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oxygen consumption that is estimated
to be coupled to ATP synthesis, at rest
25–30% is accounted for by protein
synthesis [17]. A fall in protein synthesis
would thus be advantageous when
oxygen is scarce [15]. Indeed, in some
animals ATP demand for protein syn-
thesis can fall by 93% under hypoxic
conditions [14]. Second, the ensuing
weight loss might itself improve the
economy of movement [18]. Meanwhile,
thinner myocytes also contribute to an
enhanced muscle capillary density [19,
20] and therefore perhaps improved
oxygen delivery as a result of shorter
diffusion distances. Finally, loss of
muscle results in loss of total mitochon-
drial mass, whilst with prolonged expo-
sure to hypoxia at high altitude,
mitochondrial density falls in the
remaining muscle, further decreasing
oxygen demand [3, 21].Ketones as metabolic
substrates
But could there be an advantage to the
release of amino acids and ketone
bodies? Certainly both are metabolic
fuels. Ketone bodies, in particular, can
substitute for glucose as energy sub-
strates for the brain, and indeed most
other tissues, during starvation and
heavy exercise [22]. Concentrations of
b-OHB, for instance, are normally very
low (0.1mmol/L), but can rise 13-fold
in humans during prolonged starvation,
with increased cerebral ketone uptake
contributing substantially to cerebral
metabolism [23]. Under conditions of
starvation or exercise, when exogenous-
ly acquired glucose becomes depleted,
there is a clear advantage to promoting
the hepatic synthesis of ketones –
largely derived from endogenous fat
reserves – because fatty acids are
themselves unable to cross the blood-
brain-barrier, and are thus able to make
only a negligible contribution towards
satisfying cerebral energy demands.
However, the advantage of reducing
calorie intake at altitude, only to
substitute exogenous energy sources
with those endogenously derived, is
not obvious, particularly since, in
general, natural selection has favoured
a state of positive energy balance in
humans [24].Bioessays 36: 721–729, 2014 The Authors. BKetones lower the oxygen cost
of ATP synthesis compared
with fatty acids
It is likely, therefore, that ketones offer
some advantage over glucose as a fuel.
But what might that be? Certainly, the
elevation in b-OHB seen in prolonged
human starvation is associated with
a decrease in respiratory quotient
(RQ; CO2 produced/O2 consumed) [25].
Whilst the ventilatory cost associated
with CO2 clearance would therefore be
reduced under such circumstances, it is
doubtful that this alone would offer
significant advantage to survival or
performance at altitude, particularly
since, in the context of altitude, venti-
latory drive is increased because of
hypoxia [1]. The ATP yields of ketone
and glucose oxidation per 2-carbon unit
are similar, and in this regard both are
inferior to fatty acids [22]. Whilst, during
starvation, lipolysis of triglyceride
stores might enhance fatty acid avail-
ability and drive oxidation in tissues
other than the brain, the increased ATP
yield comes at a price. The oxygen cost
of fatty acid oxidation is greater than
that of either ketones or glucose,
and is worsened further by the fatty
acid driven activation of mitochondrial
uncoupling proteins (UCPs) and peroxi-
somal fatty acid oxidation, which yields
no ATP [22]. Indeed, under sustained
hypoxic conditions, fatty acid oxidation
is suppressed in cultured cells and
human skeletal muscle [3, 21].
So is this apparent switch to endog-
enous fuels simply the price of catabo-
lism? Or could there be advantages to
increased ketone and amino acid flux?The advantages of
enhanced ketone
synthesis
That a switch to ‘different fuels’ might
be advantageous is suggested by the
fact that hypoxia not only drives
ketogenesis through relative starvation,
but also directly augments ketone
synthesis, just as it does protein catab-
olism: in neurons, at least, hypoxia
induces AMPK, which itself may en-
hance ketone flux [26]. Also suggestive
of an advantage to ketogenesis in
these circumstances is the fact thatioessays published by WILEY Periodicals, Inc.ketones protect the brain in situations
where the balance of oxygen/substrate
delivery and use is unfavourable, for
example during ischaemia/hypoxia;
b-OHB reduces cerebral infarct size
following ischaemic stroke [27, 28].Ketones decrease reactive
oxygen species production via
uncoupling
Such effects may be partly mediated via
decreased reactive oxygen species
(ROS) production [29]. Ketogenic diets
raise hippocampal glutathione peroxi-
dase activity fourfold [30] and mito-
chondrial uncoupling protein 2 (UCP2)
expression by 55%, reducing ROS pro-
duction to a similar degree [31]. Like-
wise, consumption of a novel ketone
ester diet increased levels of the other
brain uncoupling protein isoforms,
UCP4 and UCP5, to a similar extent [32].
Although increased uncoupling might
exacerbate tissue hypoxia, due to the
increased oxygen required in order to
maintain ATP synthesis, the antioxidant
effect elicited by mild uncoupling
might, under these circumstances, out-
weigh the harm.Ketones protect mitochondrial
function independently of
effects on ROS production
Ketones seem to have other protective
mitochondrial effects, however, inde-
pendent of those mediated through ROS
modulation. Rotenone (an inhibitor of
the mitochondrial electron transport
chain complex I) causes dose-depen-
dent synaptic inhibition independent of
changes in ROS levels (and unaffected
by the application of antioxidants),
whilst ketone supplementation reverses
the rotenone-induced decrease in ATP
levels [33]. Ketones divert glucose from
oxidative metabolism towards replen-
ishment of Krebs cycle intermediates
(anaplerosis), one of which (propionate,
metabolized to succinyl-CoA to enter
the Krebs cycle), protects the heart
from ischaemia-reperfusion injury [34].
Meanwhile, the cytotoxic agent 1-meth-
yl-4-phenylpyridinium inhibits cultured
neuronal mitochondrial NADH dehy-
drogenase activity, impeding electron
transport and increasing free radical723
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and cell death. Exposure to b-OHB
increases cell survival under such
circumstances [35], as it does when
such cells are exposed to rotenone [36].Ketones improve mitochondrial
metabolic efficiency
Ketone exposure also improves mito-
chondrial metabolic efficiency: oxygen
consumption in isolated perfused work-
ing rat hearts falls, whilst mechanical
work output increases [37]. Similar
effects are seen in mammalian sperm,
whose motility is increased with b-OHB
exposure, whilst oxygen consumption
falls [38]. Such effects may be mediated,
in part, through oxidation of the co-
enzyme Q couple and reduction of
the nicotinimide adenine dinucleotide
(NAD) couple; this increases energy
release as an electron travels the
electron transport chain, and thus the
free energy release from ATP hydrolysis.
In essence, the reactants in one step of
ATP synthesis (NADH/NADþ), become
more reduced while those at the next
step (Coenzyme Q/Coenzyme QH2),
become more oxidized, ‘widening the
energetic gap between the two’ [39].
Such a gain in metabolic efficiency
would clearly be advantageous under
conditions where oxygen availability is
relatively low.Ketones elicit hypoxic
protection via effects on KATP
channels
Ketones may also regulate metabolism
(and offer hypoxic protection) through
effects on ATP-sensitive potassium
channels (KATP channels). These have
two integral subunits: the inward recti-
fier K channel 6 (Kir6.1/Kir6.2, a pore-
forming subunit) and the sulfonylurea
receptor (SUR), inhibited by ATP and
sulfonylurea drugs, respectively. Con-
versely, nucleotide hydrolysis by SUR
causes channel opening, maintained by
the resultant Mg-ADP. The ATP/ADP
ratio is thus a key determinant of KATP
state. KATP channels thus function as
molecular rheostats, matching cellular
energy demands to membrane poten-
tial-dependent functions. Short periods
of ischaemia preserve high-energy724phosphate levels and cellular viability
in the face of more severe and prolonged
ischaemia (‘ischaemic precondition-
ing’), a mechanism in which mitochon-
drial KATP channels are believed to play
a crucial role [40]. Although ischaemia
and hypoxia are not the same stress,
common elements (including, but not
confined to, HIF-1) mediate both hyp-
oxic adaptation and ischaemic protec-
tion [41, 42], with chronic hypoxia
increasing SUR2A protein (and thus
KATP channel) expression and protect-
ing cells from metabolic stress [43].
Meanwhile, the aryl hydrocarbon re-
ceptor nuclear translocator (ARNT) –
which binds the aryl hydrocarbon
receptor and HIF-1/HIF-2a – regulates
the response to hypoxia, but also
regulates expression of the Kir6.2
subunit, and thus of the KATP channel
itself [44]. Of relevance to our hypoth-
esis, ketones may open the KATP
channel, eliciting the neuronal effects
that might underlie their anticonvul-
sant properties [45]. There is, of course,
no reason to believe that such effects
would be confined only to neuronal
channels. Indeed, ketones also open
KATP channels in myocytes [46]. In
summary, when cellular energetics are
compromised by hypoxia, KATP chan-
nel opening preserves viability and
function [47] – and this might be
augmented by ketones.Ketones interact with HIF
signalling pathways
Thus, hypoxia induces catabolism and
the synthesis of ketones, which act as
metabolic regulators. Additionally,
ketones may also interact with hypoxia
signalling itself. Ketone utilization ele-
vates intracellular succinate, increasing
HIF-1 levels [48]. Increased cerebral
HIF-1, induced by b-OHB or a ketogenic
diet, is associatedwith reductions of 55–
70% in cerebral infarct volumes in
experimental ischaemic stroke [49].
Thus, ketones may both mediate HIF-
dependent responses to hypoxia, and
also help to regulate them. In the
context of hypoxia, ketones help main-
tain mitochondrial membrane potential
and decrease hippocampal neuronal
death [50], and prevent rises in rat
cerebral lactate concentrations [51]. For
all of these reasons, ketones mightBioessays 36: 721–729, 2014 The Authors. Biobenefit all aerobic cells exposed to
hypoxia [39].The advantages of
enhanced amino acid
availability
Inhibition of protein synthesis
and regulation of mitochondrial
function by mTOR
Whilst hypoxia inhibits mTOR, and thus
protein synthesis [52, 53], mTOR is also a
key regulator of mitochondrial function
and oxidative capacity [54]. It thus
orchestrates both a catabolic and meta-
bolic response to hypoxia. The
branched chain amino acids interact
with mTOR to modulate this re-
sponse [55] whilst having their own
direct effects: leucine, for instance,
inhibits mitochondrial oxidative phos-
phorylation, thereby decreasing oxygen
demand [56]. Amino acid release from
muscle might maintain availability (and
thus hypoxic protection) when inges-
tion is reduced in order to drive ketone
synthesis. Alternatively, the catabolic
response might augment cellular avail-
ability beyond that found under normal,
fed, conditions, when insulin stimulates
the uptake of amino acids into tissues
and the synthesis of proteins in a variety
of ways. In addition to possible roles as
metabolic substrates in their own right,
a number of amino acids elicit protec-
tive responses that might be beneficial
under hypoxic conditions.Glycine protects renal tubules
in hypoxia
Glycine protects isolated renal proximal
tubule cells against a wide range of
chemical inhibitors of oxidative phos-
phorylation (e.g. rotenone, cyanide and
carbonyl cyanide m-chlorophenylhy-
drazone (CCCP)) without itself support-
ing cellular respiration and ATP
synthesis [57]. Moreover, glycine offers
potent, ROS-independent, hypoxic pro-
tection to isolated renal proximal tubu-
lar cells [58] and human umbilical
endothelial cells [59]. Such effects seem
to be highly structurally specific, being
confined (in studies of more than 45
amino acids and analogues) to glycineessays published by WILEY Periodicals, Inc.
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over, the effects seem to be independent
of amino acid metabolism [60, 61],
glutathione accumulation [57] or
changes in intracellular pH [62], and
currently remain inadequately explained
[63]. Whatever the mechanism, these
amino acids may play an important role
in the protection of (at least) renal
tubular cells in the face of hypoxia.Taurine protects mitochondrial
function
Meanwhile – taurine, not one of the
canonical 20 amino acids encoded by
DNA but one that is derived from
cysteine – protects against ischaemia-
reperfusion injury [64, 65] and improves
respiratory chain activity in sepsis [66].
Regardless of whether taurine exerts
these effects solely through its anti-
oxidant properties or through non-
mitochondrial effects (including altered
ROS activity), effects on mitochondrial
function, including protection against
arsenic-induced apoptosis and oxida-
tive stress [67] and improved calcium
buffering [68], have been demonstrated.Glutamine regulates the cellular
response to hypoxia
Plasma glutamine is a mitochondrial
substrate, and a glutamate precursor.
Hypoxia stimulates its uptake and
regulates its metabolism in a variety
of cells [69–72]. Consistent with such
increased flux, plasma levels fall in
humans exposed to high-altitude for
three weeks [73], despite presumed
increased release due to skeletal muscle
catabolism over this time. However,
glutamine is not just a substrate, but
a metabolic modulator [74] regulating
the response to hypoxia. It protects cells
from oxidative stress [75], preserves
anoxic heart function [76], protects
the gut [77], lung [78], liver [79] and
kidney [80] from ischaemia/reperfusion
injury, modulates the cardiac precondi-
tioning response [81] and acts as a
preconditioning agent in its own
right [82]. Such effects may, to some
degree, be HIF-dependent: in human
prostate (DU-145) and pancreatic
(MiaPaCa-2) cancer cells exposed to
hypoxia, deficiency of glutamine (butBioessays 36: 721–729, 2014 The Authors. Bnot pyruvate) suppresses the associat-
ed rise in HIF-1a levels, seemingly
through translational disruption [83].
Glutamate, meanwhile, is a powerful
modulator of the activity of adenosine
monophosphate (AMP)-activated ki-
nase (AMPK), a metabolic sensor [84,
85]; at least in tumours, it is essential
for the expression of hypoxia-induced
factors such as vascular endothelial
growth factor [86].Synergistic effects of
elevated ketones and
amino acids
Thus, both ketones and amino acids
may act independently as both meta-
bolic fuels and metabolic modulators.
In addition, however, amino acids
released from the skeletal muscle pool
might also act synergistically with
ketoacids to further regulate the human
metabolic response to hypoxia. Thus,
glutamic acid can be deaminated by
glutamate dehydrogenase to yield a-
ketoglutarate. Supplementation of a-
ketoglutarate (a-KG) in combination
with aspartate both prevents and
reverses hypoxia/reoxygenation-in-
duced impairments in mitochondrial
metabolism (and of complex I function,
specifically) [87]. Anaerobic metabolism
of these agents yields ATP and main-
tains mitochondrial membrane poten-
tial, as do other citric acid cycle
intermediates that can promote anaero-
bic metabolism, such as fumarate or
malate (whether alone, or in combina-
tion with a-KG). Succinate, the end-
product of these anaerobic pathways,
can bypass complex I, but it protects
only when applied during reoxygena-
tion and not when applied only during
hypoxia [87]. Thus, renal tubule cells
subjected to hypoxia/reoxygenation
suffer complex I dysfunction, which
is prevented/reversed by citric acid
cycle metabolites that anaerobically
generate ATP and which maintain
mitochondrial membrane potential
via electron transport at complex
I [88]. The pathways that allow metab-
olism of citric acid cycle intermediates
exist in other human tissues, and may
thus represent a means of more general
systemic protection in the face of
hypoxia [59, 88].ioessays published by WILEY Periodicals, Inc.Future studies, clinical
and evolutionary
perspectives
Does the hypoxic catabolic
state differ from the response
to fasting alone?
The hypoxic catabolic state (which we
propose to be beneficial) thus appears
largely due to a negative energy balance
resulting from prolonged restriction of
caloric intake. However, this is aug-
mented by hypoxic inhibition of skeletal
muscle protein synthesis. In addition,
unlike the usual metabolic response
to fasting, hypoxic acclimatization is
associated with a shift in substrate
preference away from, rather than
towards, fatty acid oxidation in cardi-
ac [89] and skeletal muscle [21]. The
difference may in part lie with the
regulation of peroxisome proliferator-
activated receptor a (PPARa) and its
downstream factors. Suppressed (at
least in some tissues) in a HIF-1-
dependent manner in the hypoxic
setting [90], PPARa is, by contrast, a
vital factor in the response to normoxic
starvation, withmice deficient in PPARa
failing to activate pathways of fatty
acid oxidation and promote hepatic
ketogenesis [91]. In liver, activity of
the (mTOR-containing)mTOR complex 1
(mTORC1) is suppressed in fasting,
hence relieving inhibition of PPARa
and thereby promoting fasting-induced
ketogenesis [92]. Hypoxic inhibition of
mTOR itself, which in muscle inhibits
protein synthesis, might therefore
rescue the PPARa-supported hepatic
ketogenesis under hypoxic conditions,
perhaps underlining the importance of
this mechanism for survival.Further studies
The nature of the hypoxic catabolic
state, and how it might differ from
starvation or calorie restriction under
normoxic conditions, thus clearly
deserves further attention. Metabolic
flux studies, with particular attention
paid to ketone biosynthesis and oxida-
tion, could establish the changes in
substrate flux that occur in response to
prolonged hypoxia. Such studies could
be carried out in humans, either at725
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animal models of hypoxia. Pair-fed
normoxic control subjects would be
vital components of all of these studies
in order to establish the precise role of
hypoxia – as a distinct contributor from
the reduced calorie intake per se – in the
metabolic reprogramming that occurs in
these states. The effects of achieving
ketosis at altitude by dietary means
might also deserve investigation. Would
a ketogenic diet or non-toxic ketone
ester supplementation prevent muscle
wasting at altitude or in simulated
hypoxia, and might it improve exercise
efficiency? Moreover, it would be inter-
esting to investigate whether those
individuals that lose the most weight
at altitude, and particularly those who
predominantly lose lean mass, fare
better in terms of exercise performance.
Further, are these patterns of weight
loss, largely observed in lowlanders,
replicated in high-altitude natives? In
addition, the putative protective effects
of amino acids at physiological concen-
trations on mitochondrial function –
whether alone or in combination with
ketone bodies – deserves further study
in the light of recent technical develop-
ments including more sensitive means
of measuring oxygen consumption and
ROS generation.Clinical and evolutionary
perspectives
Given that humans probably evolved
close to sea level, the human cachectic
response to high altitude, at least in
lowland natives, is unlikely to have
resulted from altitude-related selection
pressure. Perhaps a response of value at
sea level, has later shown benefit at
altitude?
Thus, the reduced oxygen availabil-
ity associated with haemorrhage (such
as that which occurs near the time of
childbirth) engenders an erythropoietic
response, which helps restore oxygen
transport. However, an exaggerated
erythrogenic response to the hypoxia
of altitude can prove lethal [93]. Indeed,
later natural selection in Tibetan natives
has favoured lower circulating haemo-
globin levels than those seen in low-
landers ascending to altitude [94].
Perhaps the catabolic state repre-
sents an advantageous adaptive re-726sponse at sea level, the benefit of
which becomes clearer upon exposure
to the severe systemic hypoxia of
altitude? The human response to the
hypoxia of high altitude shares many
features with disease states in which
reduced oxygen availability plays a
role [95]: similar patterns of weight
loss, muscle wasting and altered cellu-
lar metabolism are noted in chronic
obstructive pulmonary disease
(COPD) [96, 97] and heart failure [98],
for instance. Perhaps wasting offers a
survival advantage when disease states
are complicated by reduced cellular
oxygen delivery, and it is this response,
which has been selected for.
Likewise, in the critically ill, loss of
muscle mass occurs early and rapidly,
and is associated with an inhibition of
protein synthesis [99]. Loss of adipose
mass also occurs. Could it be that these
responses are protective rather than
maladaptive? One is minded of the
folklore advice to ‘feed a cold, but
starve a fever’. Certainly, the adminis-
tration of parenteral nutrition (when
enteral nutrition is not possible) does
not improve patient outcome in the
critically ill [100], and active efforts
to supplement intake in order to
meet calorie targets may in fact be
harmful [101]. Perhaps, just as at
altitude, cachexia in ICU might offer
short or medium-term metabolic
advantages that aim to protect against
cellular injury, albeit that this
may ultimately lead to profound weak-
ness in many patients [102]. The
potential for ketosis as a therapeutic
intervention, or the administration of
ketone bodies as an energy source,
thus deserves investigation, and might
obviate the need for muscle degenera-
tion in order to support survival at all
costs.
Thus, whilst cachexia in response
to hypoxia at altitude may offer a
survival or performance advantage, it
perhaps has its origins in protection
under circumstances in which tissue
oxygen delivery was impaired due to
injury or illness, for instance following
haemorrhage or septic shock. If this is
indeed the case, the rapid loss of
muscle mass in ICU patients may more
closely reflect the evolutionary origins
of hypoxia-induced cachexia and its
possible benefits, than the high alti-
tude condition.Bioessays 36: 721–729, 2014 The Authors. BioConclusions and outlook
Sustained exposure to cellular hypoxia,
whether in the context of ascent to high
altitude or as a consequence of critical
illness, threatens cell function and
survival. Established features of the
hypoxia response include measures to
maintain blood oxygen content (e.g. via
erythropoiesis) and reduce tissue oxy-
gen demand (e.g. by inhibition of
mitochondrial oxidative phosphoryla-
tion and possibly by a loss of mitochon-
drial density).
We now propose that the catabolic
response to sustained hypobaric hypox-
ia not only contributes to reduced
oxygen demand (e.g. by reducing those
costs associated with protein synthesis),
but also acts to further modulate
metabolism and to augment cellular
hypoxic protection (Fig. 2). Specifically,
we postulate that ketone bodies are
synthesized as a result of lipolysis and
amino acids released by muscle break-
down; that hypoxia augments both
ketone synthesis and amino acid avail-
ability; that increased amino acid flux
can augment ketogenesis; and that both
ketones and amino acids act not only as
metabolic fuels, but also as metabolic
modulators, offering generalized or
tissue-specific hypoxic protection.
Ketones decrease the O2 cost of ATP
synthesis, lessen cerebral ROS produc-
tion and open KATP channels, whilst
interacting with hypoxia signalling
pathways. Meanwhile, certain amino
acids protect mitochondria (e.g. taurine)
and cellular function in hypoxia (e.g.
glycine), whilst glutamine further mod-
ulates the cellular response to hypoxia.
We propose that such responses may be
common to many illnesses at sea level,
in which strategies to augment ketone
and amino acid delivery might offer
therapeutic advantage.
The concepts presented here could
be verified using metabolic flux studies
in subjects at altitude (real or simulat-
ed), and the therapeutic impacts of
combined ketone/amino acid delivery
assessed in disease states such as
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Figure 2. Sustained exposure to hypobaric hypoxia results in cachexia. Fatty acids are
released from adipose tissue by lipolysis, whilst muscle breakdown releases amino acids.
Fatty acids and some amino acids are converted into ketone bodies by the liver. Ketone
bodies and amino acids act as metabolic substrates, but also as metabolic modulators,
eliciting protective effects on cells via a myriad of general or tissue-specific mechanisms.
Thus, we propose that the hypoxia-induced cachexia at high altitude is protective. Leu,
leucine; Gly, glycine; Tau, taurine; Gln, glutamine; OXPHOS, oxidative phosphorylation; ROS,
reactive oxygen species; KATP channels, ATP-activated potassium channels.
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